Sanofi and GSK announce today the start of the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
The Phase 1/2 clinical trial is a randomised, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the COVID-19 vaccine candidate. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States.
The Companies anticipate first results in early December 2020, to support the initiation of a Phase 3 trial in December 2020. If these data are sufficient for licensure application, it is planned to request regulatory approval in the first half of 2021.
https://www.gsk.com/en-gb/media/pre...-recombinant-protein-based-vaccine-candidate/
Which strain will this be for? Wonder when we can expect vaccines for the other 29+?
Covid 19 has mutated into at least 30 strains